B+
Bull case
25%
Probability
Target price
$680.00
Analysis reference price unavailable
Analysis 2026-07-28 · RankAlpha Sentiment Codex
TMO
Thermo Fisher ScientificBNYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
55%
Probability
Target price
$630.00
Analysis reference price unavailable
Analysis 2026-07-28 · RankAlpha Sentiment Codex
B-
Bear case
20%
Probability
Target price
$500.00
Analysis reference price unavailable
Analysis 2026-07-28 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-07-28
Recent news sentiment (30D)
+0.8
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+64.9
Score
AI commentary
News tone is strongly positive after the Q2 beat and outlook increase, and the available price check shows the initial reaction holding. One post-print target increase was identified, but broader analyst revisions remain unavailable; social, options, short-interest, and employee-sentiment data are absent. Maintain a constructive but monitoring-oriented view.
RankAlpha Sentiment Codex - 2026-07-28
Open post-earnings memoEvidence flagged
high-coverage report lacks a dated company-specific catalyst beyond generic cadence; peer set is too generic or lacks enough direct operating comparators
Impact
tentative
Confidence
-
AI events
2026-07-23eventQ2 beat and higher 2026 outlookMedium impact
The SEC-filed earnings exhibit confirms Q2 revenue of $11.99 billion, 5% organic growth, GAAP EPS growth of 9%, adjusted EPS growth of 13%, and strengthening end-market activity [#SEC-8K-2026-07-23]. Stored earnings context reports results above expectations and updated FY2026 revenue guidance of $47.4-$48.1 billion and adjusted EPS guidance of $24.93-$25.33, although the packet lacks a full consensus table [#PR-EARNINGS-2026-07-24].
2026-07-28catalystPositive post-earnings price reactionMedium impact
Investing.com reported an approximately 9% intraday gain on July 23 after the earnings release, with the move attributed to the earnings beat and higher full-year outlook. The available July 28 quote check remained above the packet anchor, indicating that the initial reaction held through the observed period.
2027-07-28catalystStrengthening customer activity and capability-led growthHigh impact
The company highlighted improving customer activity, new AI-enabled Orbitrap platforms, a U.S. Bioprocess Design Center, and a precision-medicine collaboration. These provide dated company-specific support for medium-term commercial uptake, but incremental economics and durability remain unquantified [#SEC-8K-2026-07-23].
Recommendation
N/A
No formal recommendation provided.
As of 2026-07-28 • Updated nightlySource: Internal modelMethodology